by Lupus Foundation, Ohio | Aug 12, 2026 | Lupus Foundation of America, News & Events
A new study identified 39 candidate measures for an updated tool to better assess long-term organ damage in people with systemic lupus erythematosus (SLE). This post was originally published on this...
by Lupus Foundation, Ohio | Jul 30, 2026 | Lupus Foundation of America, News & Events
A new study of adults with systemic lupus erythematosus (SLE) found cerebral atrophy or brain shrinkage is linked to older age, longer disease duration, lower education levels, presence of neuropsychiatric systemic lupus erythematosus (NPSLE), and more severe disease...
by Lupus Foundation, Ohio | Jul 28, 2026 | Lupus Foundation of America, News & Events
A new study found that higher glucocorticoid (steroid) exposure and limited practical social support were associated with an increased risk of long-term neuropsychiatric damage in people with systemic lupus erythematosus (SLE). This post was originally published on...
by Lupus Foundation, Ohio | Jul 16, 2026 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to EMD Serono’s investigational drug, enpatoran, for the treatment of systemic lupus erythematosus (SLE) in those with active cutaneous skin manifestations. This post was...
by Lupus Foundation, Ohio | Jul 14, 2026 | Lupus Foundation of America, News & Events
Holly Wobma, MD, Ph.D., Instructor of Pediatrics, Harvard Medical School. Dr. Wobma will be studying CAR-Treg’s capacity to restore immune balance and subsequent disease remission in children with lupus. This post was originally published on this...
by Lupus Foundation, Ohio | Jul 14, 2026 | Lupus Foundation of America, News & Events
A new study found a lectin-based test can effectively detect certain complex sugar molecules (glycans) on the Fc region of immunoglobulin (IgG) antibodies. The lectin-based test may eventually help to spot early changes in glycosylation which has been linked to...
